Open
Actively Recruiting
Registry for Participants With Short Bowel Syndrome
About
Brief Summary
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS).
- Signed informed consent and medical records release by the participant or a legally acceptable representative
- Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment.
Exclusion criteria:
- Participants currently participating in a blinded clinical trial or their extension studies.
- Participants who have never been on PN/IV support.
- Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide.
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
18-000700
Category
Oncology
Surgery
Principal Investigator
Contact
Location
- UCLA Westwood